Search | Schedule | Author Index | eBook | Personal Scheduler

Author Index: H

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Haider, S.
COS3-4   HEALTHCARE RESOURCE USE AND COSTS ANALYSIS FROM A CHINESE PAYER PERSPECTIVE OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS NOSOCOMIAL PNEUMONIA (MRSA-NP) PATIENTS TREATED WITH LINEZOLID OR VANCOMYCIN, WITH A FOCUS ON PATIENTS DEVELOPING RENAL FAILURE
Hajek, P.
BUDGET IMPACT ANALYSIS OF LINEZOLID IN THE TREATMENT OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) CONFIRMED NOSOCOMIAL PNEUMONIA IN CHINA
Harahap, U.
DRUG RELATED PROBLEMS AND THEIR ASSOCIATION WITH HOSPITAL LENGTH OF STAY OF PNEUMONIA PATIENTS
Hawley, S. T.
COS4-1   CAN AN INTERACTIVE DECISION AID IMPROVE SHARED DECISION MAKING? PRELIMINARY BASELINE RESULTS FROM DATES (DECISION AID TO TECHNOLOGICALLY ENHANCE SHARED DECISION MAKING)
Heng, B. H.
COS2-4   COST-EFFECTIVE SCREENING FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COLONIZATION UPON HOSPITAL ADMISSION
Hidaka, I.
COST-EFFECTIVENESS OF 72-WEEK VS. 48-WEEK TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED JAPANESE PATIENTS
Hidayah, N.
DRUG RELATED PROBLEMS AND THEIR ASSOCIATION WITH HOSPITAL LENGTH OF STAY OF PNEUMONIA PATIENTS
Hing, W. C.
OPTIMIZING REPACK SIZES FOR OUTPATIENT PHARMACY AUTOMATED DISPENSING SYSTEMS
Hoch, J.
COS3-5   USING HEALTH CARE ADMINISTRATIVE DATA TO ESTIMATE COSTS FOR ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER PATIENTS

INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT
Hoffmann, T. C.
NAIVELY OPTIMISTIC? A SYSTEMATIC REVIEW OF PATIENTS' EXPECTATIONS OF THE BENEFITS AND HARMS OF TREATMENTS, SCREENING, AND TESTS

COS1-1   A RANDOMISED TRIAL OF TRAINING STUDENT CLINICIANS IN HOW TO FACILITATE SHARED DECISION MAKING AND COMMUNICATE EVIDENCE: IS THIS THE IGNORED STEP IN EVIDENCE-BASED PRACTICE?
Holmes-Rovner, M.
COS4-2   PHYSICIAN ROLE IN PATIENTS' DECISIONS ABOUT PROSTATE CANCER TREATMENT
Hsieh, C. Y.
COS3-2   QUANTITATIVE RISK-BENEFIT ANALYSIS ON DOSAGE OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR IN ASIAN PATIENTS WITH STROKE THROMBOLYSIS
Hsu, J. C.
COS3-2   QUANTITATIVE RISK-BENEFIT ANALYSIS ON DOSAGE OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR IN ASIAN PATIENTS WITH STROKE THROMBOLYSIS
Humphries, K.
COS4-5   VALUATION OF PATIENT AND PHYSICIAN PREFERENCES FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z